Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cartesian Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Cartesian Therapeutics, Inc.

RNAC

Cartesian Therapeutics, Inc.

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics is a biotech company developing mRNA cell therapies for autoimmune diseases. Its lead product, Descartes-08, is an autologous mRNA CAR-T targeting BCMA, designed to treat conditions like myasthenia gravis and systemic lupus erythematosus. The company leverages proprietary technology to create outpatient, repeat-dosed treatments that aim to provide deep, durable, and safer immune modulation without pre-treatment chemotherapy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cartesian Therapeutics, Inc.

1
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports $39.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports $130.3 Million Net Loss for 2025, Revenue Drops to $2.8 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports 95% Revenue Decline in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports Q2 2025 Revenue Decline to $298,000 Amid Increased Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports Revenue Decline and Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports $77.4 Million Net Loss for 2024, Revenue Increases to $38.3 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cartesian Therapeutics, Inc. Cartesian Therapeutics Reports Decline in Revenue, Net Loss, and Increased Cash Reserves in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments